CA-AMBLIN-PARTNERS
Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman.
Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratulations on what I know will be a successful next chapter in Participant’s journey. While in a different form, we look forward to continuing our collaborations to create the type of culturally-impactful content that only Participant can deliver.”
Donna Langley, Chairman, Universal Filmed Entertainment Group, said: “Steven Spielberg and Amblin Partners have delivered award-winning critical and commercial hits that stand the test of time amongst films in the Universal canon. We’re proud to continue our partnership and reinvest in the future of Amblin Partners.”
Amblin’s continuing partnership with Universal Filmed Entertainment Group builds on a long history between the two companies, dating back to Spielberg’s arrival on the Universal lot as an intern in 1968. The new agreement further evolves the entities’ 2015 agreement that resulted in a number of critical and commercial hits, most recently Oscar Best Picture Winner Green Book, and 1917 , which won three Oscars, two Golden Globes and grossed more than $385 million at the worldwide box office.
The new deal calls for multiple Amblin films to be marketed and distributed theatrically via Universal Pictures and Focus Features each year, while also providing Amblin with new opportunities in the streaming film marketplace. NBCUniversal has also agreed to re-invest in the Company, continuing its position as an equity holder and providing fresh capital to fund new production and development efforts across the Company’s film and television businesses.
Jeff Small, Amblin Partners CEO, commented: “Universal is simply the best in the business, and we are beyond fortunate to have Donna Langley and her team supporting our films. In addition, the evolution of our partnership provides flexibility for us to continue supplying the fast-growing streaming marketplace on an even greater scale, which will no doubt be a key growth driver for Amblin Partners in both film and TV in the years ahead.”
Alibaba Pictures, eOne and Reliance Entertainment will all continue as equity holders, with Alibaba releasing Amblin films in China; eOne releasing in the U.K., Spain, Australia, New Zealand and Benelux; and Reliance releasing in India.
Participant, which as a founding partner played a key role in the formation of Amblin Partners in 2015, will now exit its role as an equity holder of the Company. This transition will allow Participant flexibility with respect to distribution of its films, while still keeping open opportunities to work together with Amblin on future projects.
“We have enjoyed our relationship with Amblin Partners and are proud of the many notable films we have produced together,” stated Participant CEO David Linde. “Exiting our formal position will allow us the flexibility to evolve our business as our strategic goals and the marketplace dictates. Both Universal and Focus have been great distribution partners; and we have been incredibly fortunate to work closely with Steven, well pre-dating the formation of Amblin Partners, and look forward to finding new projects with him, Jeff Small and the entire Amblin team.”
Amblin also announced the close of an amended and restated syndicated revolving credit facility led by J.P. Morgan and Comerica. The facility continues longstanding relationships with a number of additional banking partners, and in total includes City National Bank, Union Bank, Wells Fargo Bank, Bank Hapoalim, CIT Bank, East West Bank, Fifth Third Bank, California Bank & Trust, Citizens Bank and Preferred Bank. The facility will fund ongoing corporate operations, as well as production and development activities for both film and television.
“For nearly three decades, J.P. Morgan has had the pleasure of working with Amblin through its many significant achievements and milestones,” said David Shaheen, Head of the West Region and Entertainment Industries Group for J.P. Morgan’s Corporate Client Banking business. “We are proud to support the ambitious and creative Amblin team as they write the next chapter of their impressive story.”
About Amblin Partners
Amblin Partners is a film and television production company, led by Steven Spielberg, that develops and produces films using the Amblin Entertainment and DreamWorks Pictures banners, and includes Amblin Television. The Company’s investment partners include Reliance Entertainment, Entertainment One (eOne), Alibaba Pictures and Universal Pictures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005872/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom